Search results for "PIDE"

showing 10 items of 6055 documents

A first-in-human trial of RG7116, a glycoengineered monoclonal antibody targeting HER3, in patients with advanced/metastatic tumors of epithelial cel…

2013

2522 Background: The Human Epidermal Growth Factor Receptor 3 (HER3) is a key heterodimerization partner for other HER family members thereby acting as a downstream signal amplifier. This is a first in human study evaluating the safety of RG7116, a humanized anti-HER3 monoclonal antibody with potent HER3 signal inhibition. Due to a glycoengineered Fc-part this antibody displays enhanced antibody-dependent cellular cytotoxicity as compared to conventional antibodies. Methods: Patients (pts) with advanced or metastatic carcinomas with centrally confirmed HER3 protein expression were included. A “3+3” dose escalation design was performed starting at 100 mg flat dosing in a q2w regimen. In add…

Cancer Researchmedicine.drug_classbusiness.industryFirst in humanMonoclonal antibodyEpitheliumSignal amplifiermedicine.anatomical_structureOncologyDownstream (manufacturing)Cancer researchmedicineHuman epidermal growth factor receptorIn patientbusinessJournal of Clinical Oncology
researchProduct

Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma

2020

BackgroundWe have previously reported significantly longer overall survival (OS) with ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with advanced melanoma, with higher incidences of adverse events (AEs) at 10 mg/kg. This follow-up analysis reports a 5-year update of OS and safety.MethodsThis randomized, multicenter, double-blind, phase III trial included patients with untreated or previously treated unresectable stage III or IV melanoma. Patients were randomly assigned (1:1) to ipilimumab 10 mg/kg or 3 mg/kg every 3 weeks for 4 doses. The primary end point was OS.ResultsAt a minimum follow-up of 61 months, median OS was 15.7 months (95% CI 11.6 to 17.8) at 10 mg/kg and 11.5 mont…

Cancer Researchmedicine.medical_specialty2435[SDV]Life Sciences [q-bio]ImmunologyMedizinIpilimumabrandomized trialsGastroenterologyAsymptomaticlaw.inventionimmunology03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicineClinical endpointImmunology and Allergy1506030212 general & internal medicineAdverse effectRC254-282Clinical/Translational Cancer ImmunotherapyPharmacologybusiness.industryIncidence (epidemiology)MelanomaNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseimmunology; oncology; randomized trials[SDV] Life Sciences [q-bio]Oncology030220 oncology & carcinogenesisoncologyMolecular Medicinemedicine.symptombusinessBrain metastasismedicine.drug
researchProduct

A survey of seroprevalence of human papillomavirus types 16, 18 and 33 among children.

1999

The importance and natural history of HPV infections in childhood is incompletely understood. We performed a survey for presence of serum antibodies to HPV capsids among 1031 children aged 0 to 13 years, resident in Stockholm, Sweden. The HPV seroprevalence among these children was 3.0% for HPV16, 0.6% for HPV18 and 2.7% for HPV33. By comparison, among simultaneously analyzed positive control panels comprising women with CIN or healthy women with type-specific cervical HPV DNA, seroprevalence of HPV 16, 18 and 33 was 69%, 58% and 63% respectively. The results suggest that HPV infection in childhood is not common.

Cancer Researchmedicine.medical_specialtyAdolescentvirusesAntibodies ViralSerologyCapsidInternal medicineEpidemiologymedicineSeroprevalenceHumansChildPapillomaviridaeSwedenbusiness.industryPublic healthPapillomavirus InfectionsHPV infectionInfant Newbornvirus diseasesInfantmedicine.diseasefemale genital diseases and pregnancy complicationsNatural historyTumor Virus InfectionsOncologyEl NiñoChild PreschoolImmunologyFemaleViral diseasebusinessInternational journal of cancer
researchProduct

Reactions and countermeasures of medical oncologists towards the incoming COVID-19 pandemic: A whatsapp messenger-based report from the Italian colle…

2020

Background This descriptive, unplanned investigation has been undertaken to report reactions, attitudes and countermeasures which have been put in place and implemented by medical oncology units facing the COVID-19 outbreak in Southern Italy. Materials and methods Data have been retrospectively obtained from the time-related analysis of conversations via a WhatsApp messenger-based group chat between the medical directors belonging to the Italian College of Medical Oncology Directors. Overall number, intensity and time trend of conversations related to reactions during the 4 weeks of observation related to the crucial events which occurred between 24 February and 28 March, 2020 2020 are incl…

Cancer Researchmedicine.medical_specialtyGovernmentSentimental analysiCOVID-19 outbreakCoronavirus disease 2019 (COVID-19)Reactionbusiness.industryMedical oncologistSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ResearchSentiment analysisSentimental analysisWhatsApp messengerOncologyAction takenFamily medicinePandemicEpidemic spreadReactionsMedicinebusinessRaw dataMedical oncologistsHealthcare system
researchProduct

The association between extremely low-frequency electromagnetic fields and childhood leukaemia in epidemiology: enough is enough?

2010

Background: Previous pooled analyses have reported an association between magnetic fields and childhood leukaemia. We present a pooled analysis based on primary data from studies on residential magnetic fields and childhood leukaemia published after 2000. Methods: Seven studies with a total of 10 865 cases and 12 853 controls were included. The main analysis focused on 24-h magnetic field measurements or calculated fields in residences. Results: In the combined results, risk increased with increase in exposure, but the estimates were imprecise. The odds ratios for exposure categories of 0.1–0.2 μT, 0.2–0.3 μT and ⩾0.3 μT, compared with <0.1 μT, were 1.07 (95% CI 0.81–1.41), 1.16 (0.69–1.93)…

Cancer Researchmedicine.medical_specialtyLeukemiaNeoplasms Radiation-Inducedbusiness.industryEpidemiologyExtremely low frequency electromagnetic fieldsChildhood cancerOdds ratiomagnetic fieldsConfidence intervalUnited KingdomChildhood leukaemiameta-analysisIncreased riskExposure groupElectromagnetic FieldsOncologychildhood leukaemiaEpidemiologymedicineHumanspooled analysisbusinessDemographyBritish journal of cancer
researchProduct

Sun exposure and malignant lymphoma: A population-based case–control study in Germany

2007

Although some causes for malignant lymphoma are known their etiology is not well understood so far. We analyze the relationship between sun exposure and malignant lymphoma in a multicenter, population-based case-control study. Patients with malignant lymphoma (n = 710, 18-80 years) were prospectively recruited in 6 study regions in Germany. For each case, a gender, region and age-matched control was drawn from population-registers. In personal interviews, lifetime holidays spent in sunny climate, outdoor leisure activities and sunbed or sunlamp use were recorded. On basis of job task-specific supplementary questionnaires, an occupational physician assessed the cumulative working time outsid…

Cancer Researchmedicine.medical_specialtyLymphomaPopulationFollicular lymphomaLogistic regressionGermanyOccupational Exposurehemic and lymphatic diseasesEpidemiologymedicineHumansRisk factoreducationeducation.field_of_studybusiness.industryCase-control studyEnvironmental ExposureOdds ratiomedicine.diseaseSurgeryOncologyCase-Control StudiesPopulation SurveillanceSunlightRecreationPopulation studybusinessDemographyInternational Journal of Cancer
researchProduct

Incidence and patterns of late recurrences in colon cancer patients

2015

Long-term recurrences of colon cancer raised questions about the possible benefit of prolonging the recommended active 5-year surveillance. The aim of this study was to determine, for the first time, the incidence and patterns of late 10-year recurrence following curative resection of colon cancer. Data were obtained from two French digestive cancer registries. A total of 3,622 patients under 85 years resected for cure for colon cancer diagnosed between 1985 and 2000 were included. Information regarding recurrences was actively collected. Cumulative failure rates at 10 years were estimated using Kaplan-Meier estimates corrected by cause-specific hazards, and multivariable analysis was perfo…

Cancer Researchmedicine.medical_specialtyMultivariate analysisColorectal cancerbusiness.industryIncidence (epidemiology)Female sexLower riskCompeting risksmedicine.diseaseSurgeryCancer registryOncologyColon cancer resectionmedicinebusinessInternational Journal of Cancer
researchProduct

Predictive Factors for Outcome of First Allogeneic Transplant for Elderly Patients With Acute Lymphoblastic Leukemia

2021

Abstract Introduction/Background: The treatment of acute lymphoblastic leukemia (ALL) in patients older than 70 is extremely challenging with dismal outcome. Allogeneic stem cell transplantation (alloHCT) has seen many advancements in the last decades showing benefits in younger ALL patients, but this treatment modality is decreasingly used with increasing age due to high treatment-related mortality. Patients and Methods: We identified 84 ALL patients 70 to 84 years old allografted In 2002 to 2019 from a matched related (23%), unrelated (58%), haploidentical (17%), or cord blood (2%) donor at EBMT participating centers with a median follow-up of 23 months. Results: The 2-year relapse incide…

Cancer Researchmedicine.medical_specialtyMultivariate analysisTransplantation ConditioningHaploidentical transplantationGraft vs Host Disease[SDV.CAN]Life Sciences [q-bio]/CancerGraft-versus-host diseaseInternal medicinemedicineHumansTransplantation HomologousComplete remissionComputingMilieux_MISCELLANEOUSAgedRetrospective StudiesAged 80 and overUnivariate analysisCMV positivitybusiness.industryIncidence (epidemiology)Hazard ratioHematopoietic Stem Cell TransplantationHematologyTotal body irradiationPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseMinimal residual diseaseAllogeneic stem cell transplantationTransplantationLeukemia Myeloid AcuteGraft-versus-host diseaseOncologyTreatment-related mortalityAllogeneic stem cell transplantation; CMV positivity; Complete remission; Graft-versus-host disease; Haploidentical transplantation; Treatment-related mortalitybusiness
researchProduct

The prevalence and characteristics of breakthrough cancer pain in patients receiving low doses of opioids for background pain

2021

Simple Summary The aim of this study was to assess the prevalence and characteristics of breakthrough cancer pain (BTcP) in patients receiving low doses of opioids for background pain. This prospective study showed that in this population, BTcP prevalence was 69.8%. Many patients did not achieve a sufficient level of satisfaction with BTcP medications, particularly with oral morphine. Data also suggest that better optimization of background analgesia, though apparently acceptable, may limit the number of BTcP episodes. Abstract The aim of this study was to assess the prevalence and characteristics of breakthrough cancer pain (BTcP) in patients receiving low doses of opioids for background p…

Cancer Researchmedicine.medical_specialtyPain relieflcsh:RC254-282ArticleCONSECUTIVE SAMPLE03 medical and health sciences0302 clinical medicineAnalgesic therapyInternal medicineEpidemiologymedicineIn patientOral morphinebreakthrough cancer pain; opioids; dosesbusiness.industryLow doseBreakthrough cancer painlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensdosesOpioidsOncologyDose030220 oncology & carcinogenesisCancer painbusiness030217 neurology & neurosurgery
researchProduct

Italian registry of patients off therapy after childhood acute lymphoblastic leukemia. Results after first phase of data collection

1986

The Italian Registry of Off-Therapy patients after childhood tumors now includes 760 subjects with acute lymphoblastic leukemia. These patients were all removed from treatment by December 31, 1981, and were followed in 35 different institutions. All the children have received multiple-drug treatment, combined, in 79.7% of the cases, with cranial irradiation. Thirty-nine (5%) experienced a relapse before treatment suspension. Total duration of antileukemic therapy ranges between 18 and 131 months (median, 38). At the last updating (December 31, 1981), 699 subjects were alive, 6 were lost to follow-up, and 55 had died. Life-table analysis shows that 90.8% were alive and 77% were alive in cont…

Cancer Researchmedicine.medical_specialtyPediatricsbusiness.industryLymphoblastic Leukemiamedicine.diseaseOncologyEl NiñoMale patientAcute lymphocytic leukemiaEpidemiologyFemale patientmedicinebusinessChildhood Acute Lymphoblastic LeukemiaAfter treatmentCancer
researchProduct